HIV, Buprenorphine, and the Criminal Justice System

Presented in the results section are the summary of outcomes from the STRIDE RCT that were collected prior to the change in study design. The STRIDE study became STRIDE2 (NCT03583138). Those individuals originally enrolled in the STRIDE RCT will be followed for 12 months.

STRIDE2 will assist in identifying and monitoring individuals' HIV risk behaviors and provide resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to examine if there are differences in HIV, drug use, and other outcomes between individuals receiving treatment versus individuals actively using, not actively using and not in treatment, and individuals on Methadone, Suboxone, or in some other treatment.

Inclusion criteria

• HIV+
• Age ≥18 yrs
• Meets DSM-IV criteria for opioid dependence
• Has medical entitlements in DC
• Able to provide informed consent
• Able to communicate in English or Spanish

Exclusion criteria

• Being prescribed an opiate medication for a chronic pain condition or expressing the need to be placed on chronic pain medical conditions for a documented pain condition
• Currently receiving methadone dosing of over 30 mg per day and uninterested in changing to buprenorphine
• AST and ALT >5x the upper limit of normal (AST≥175, ALT≥195)
• Pregnant or unwilling to use contraception (including OCPs, patch, Depo-Provera, condoms, etc.)
• Breastfeeding or unwilling to stop breastfeeding
• Subject is part of another pharmacological research study
• Liver dysfunction (acute hepatitis, liver failure or hepatic dysfunction)
• Suicidal ideation
• Hypersensitivity to buprenorphine